Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cord blood infusions aim to slow Alzheimer's decline

NCT ID NCT07208344

Disease control Sponsor: Anhui Provincial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether infusions of cells from umbilical cord blood can help people with mild to moderate Alzheimer's disease. Thirty participants will receive either a low dose, high dose, or a placebo (salt water) through an IV once a week for four weeks, plus a fifth dose a month later. Researchers will track changes in thinking, daily living skills, and blood markers over six months to see if the treatment is safe and effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age range: 50 - 75 years old, gender not restricted; * Patients diagnosed with Alzheimer's disease (AD) according to the AT(N) diagnostic framework (with positive amyloid protein PET test results); * MMSE score between 15 and 30 points, patients with mild to moderate Alzheimer's disease; * The patient has a fixed caregiver who is willing to accompany the patient throughout the corresponding program; * The patient has a literacy level above primary school, sufficient to complete the tests stipulated in the program; * The patient or the guardian consents to participate in this clinical trial voluntarily and signs the informed consent form. Exclusion Criteria: * Dementia caused by other diseases, such as vascular dementia, frontotemporal dementia, and Lewy body dementia, etc.; * The patient has other major systemic diseases, malignant tumors, chronic obstructive pulmonary disease or pulmonary fibrosis, etc. related to the lungs; * The patient's white blood cell and neutrophil levels are below the normal lower limit; * The patient has active infectious diseases, such as syphilis, AIDS, hepatitis B, hepatitis C; * The patient has a history of stroke, epilepsy, alcohol abuse, or abuse of psychotropic drugs; * Severe visual or hearing impairment, or those who cannot complete the relevant assessment due to other reasons; * Patients who have participated in other clinical trials within the last 2 months; * Other situations that the researchers consider not suitable for participating in clinical research.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease (AD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease (AD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of the University of Science and Technology of China

    RECRUITING

    Hefei, Anhui, 230000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.